# Clover Health Reports First Quarter 2026 Results
Canonical URL: https://biopharmsignal.com/news/CLOV/clover-health-reports-first-quarter-2026-results
Ticker: CLOV
Company: Clover Health
Source: Clover Health
Published: 2026-05-06 20:05 EST
Original Source URL: https://investors.cloverhealth.com
## Summary

Business Highlights: Delivered positive GAAP Net Income in the first quarter of 2026, with strong performance across key metrics: Total revenues, Adjusted EBITDA, and Consolidated Gross Profit Market-leading Medicare Advantage membership growth with underlying trends tracking in line with

## Article Body
Business Highlights: Delivered positive GAAP Net Income in the first quarter of 2026, with strong performance across key metrics: Total revenues, Adjusted EBITDA, and Consolidated Gross Profit Market-leading Medicare Advantage membership growth with underlying trends tracking in line with
## Recent Company News
- 2026-05-06 20:05 EST — [Clover Health Reports First Quarter 2026 Results](https://biopharmsignal.com/news/CLOV/clover-health-reports-first-quarter-2026-results) — Source: Clover Health
- 2026-04-08 20:05 EST — [Clover Health to Report First Quarter 2026 Financial Results on May 6, 2026](https://biopharmsignal.com/news/CLOV/clover-health-to-report-first-quarter-2026-financial-results-on-may-6-2026) — Source: Clover Health
- 2026-04-07 12:30 EST — [Clover Health Empowers Members to Take Charge of Their Health Data Through HealthEx Partnership](https://biopharmsignal.com/news/CLOV/clover-health-empowers-members-to-take-charge-of-their-health-data-through-healthex-partnership) — Source: Clover Health
- 2026-04-01 12:30 EST — [Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026](https://biopharmsignal.com/news/CLOV/clover-health-announces-departure-of-chief-financial-officer-and-appointment-of-interim-chief-financial-officer-reiterates-most-recently-issued-financial-guidance-for-full-fiscal-year-2026) — Source: Clover Health
- 2026-03-19 12:30 EST — [Primary Care Physician Use of Counterpart Assistant Associated with 18%–22% Fewer Flu-Related Acute Care Events Among COPD and CHF Patients](https://biopharmsignal.com/news/CLOV/primary-care-physician-use-of-counterpart-assistant-associated-with-18-22-fewer-flu-related-acute-care-events-among-copd-and-chf-patients) — Source: Clover Health
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)